ArticleProceedings of the National Academy of Sciences of the United States of America1992
Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 125 citations in OpenAlex.
- From a Concept on a Chalkboard to Gapmer Antisense.ACS omega · 2026Article
- The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.Biomedicines · 2021Review
- DNA as therapeutics; an update.Indian journal of pharmaceutical sciences · 2009Article
- Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron.Nucleic acids research · 2008Article
- Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.Gene therapy · 2007Article
- Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.Journal of virology · 2002Article
- Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides.Antimicrobial agents and chemotherapy · 2001Article
- Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Journal of virology · 2000Article
- RNA double cleavage by a hairpin-derived twin ribozyme.Nucleic acids research · 2000Article
- Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Gene therapy for infectious diseases.Clinical microbiology reviews · 1998Review
- Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein.Antimicrobial agents and chemotherapy · 1997Article
- RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo.Journal of virology · 1996Article
- Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA.Nucleic acids research · 1995Article
- Antiviral therapy for human immunodeficiency virus infections.Clinical microbiology reviews · 1995Review
- Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.Journal of virology · 1995Article
- Antisense 2'-O-alkyl oligoribonucleotides are efficient inhibitors of reverse transcription.Nucleic acids research · 1995Article
- Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cells.Nucleic acids research · 1994Article
- Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.Nucleic acids research · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.